After many quarters of performance beats, Roche’s Q3 22 sales missed the street and AV expectations, mainly due to biosimilars-induced headwinds and a decline in COVID-19-related sales. However, the newer oncology portfolio, other pharma franchises and routine testing extended their good run, which also helps explain why the 2022 outlook was maintained. Overall, we remain confident of Roche’s capabilities and cushion to withstand market uncertainties, with all eyes now on the Alzheimer’s candida ....
19 Oct 2022
Soft Q3 no reason to worry
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Soft Q3 no reason to worry
- Published:
19 Oct 2022 -
Author:
Abhishek Raval -
Pages:
4
After many quarters of performance beats, Roche’s Q3 22 sales missed the street and AV expectations, mainly due to biosimilars-induced headwinds and a decline in COVID-19-related sales. However, the newer oncology portfolio, other pharma franchises and routine testing extended their good run, which also helps explain why the 2022 outlook was maintained. Overall, we remain confident of Roche’s capabilities and cushion to withstand market uncertainties, with all eyes now on the Alzheimer’s candida ....